Tumor Microenvironment Associated With Increased Pretreatment Density Of Activated Pd-1+Lag-3+/- Tim-3-Cd8+T Cells Facilitates Clinical Response To Axicabtagene Ciloleucel (Axi-Cel) In Patients (Pts) With Large B-Cell Lymphoma.

Jerome Galon,Nathalie Scholler,Regis Perbost,Sarah Turcan,Corinne Danan,Frederick Lundry Locke,Sattva Swarup Neelapu,David Bernard Miklos,Caron A. Jacobson,Lazaros J. Lekakis,Yi Lin,Armin Ghobadi,Justin Chou,Zixing Wang,Allen Xue,John M. Rossi,Adrian Bot

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 4|浏览5

暂无评分

摘要

3022Background: Axi-cel is a US and EU-approved autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy for pts with relapsed/refractory large B cell lymphoma after ≥ 2 prior therapies....

查看译文

关键词

T cell,Chimeric antigen receptor,Cytotoxic T cell,B-cell lymphoma,Tumor microenvironment,Cancer research,Refractory,Medicine,In patient

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要